期刊文献+

硼替佐米致周围神经病变的研究进展 被引量:3

原文传递
导出
摘要 硼替佐米是新型靶向治疗的抗肿瘤药物,于2003年被美国FDA批准用于多发性骨髓瘤(MM)的治疗。多项临床研究表明周围神经病变(peripheralneuropathy,PN)是硼替佐米主要的剂量限制性不良反应,影响患者的生存质量及疗效。在硼替佐米治疗的最大群体研究中,SUMMIT和CREST的Ⅱ期临床试验及APEX和VISTA的Ⅲ期临床试验结果表明,
出处 《中华血液学杂志》 CAS CSCD 北大核心 2012年第2期157-159,共3页 Chinese Journal of Hematology
  • 引文网络
  • 相关文献

参考文献21

  • 1Richardson PG,Sonneveld P,Schuster M,et al.Extended followup of a phase 3 trial in relapsed multiple myeloma:final time-toevent results of the APEX trial.Blood,2007,110:3557-3560.
  • 2Argyriou AA,Iconomou G,Kalofonos HP.Bortezomib-induced peripheral neuropathy in multiple myeloma:a comprehensive review of the literature.Blood,2008,112:1593-1599.
  • 3Prommer EE.Topical analgesic combinations for bortezomib neuropathy.J Pain Symptom Manage,2009,37:e3-5.
  • 4Richardson PG,Sonneveld P,SchusterMW,et al.Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase Ⅲ APEX trial in relapsed multiple myeloma:impact of a dose-modification guideline.Br J Haematol,2009,144:895-903.
  • 5Ravaglia S,Corso A,Piccolo G,et al.Immune-mediated neuropathies in myeloma patients treated with bortezomib.Clin Neurophysiol,2008,119:2507-2512.
  • 6Poruchynsky MS,Sackett DL,Robey RW,et al.Proteasome inhibitors increase tubulin polymerization and stabilization in tissue culture cells:a possible mechanism contributing to peripheral neuropathy and cellular toxicity following proteasome inhibition.Cell Cycle,2008,7:940-949.
  • 7Csizmadia V,Raczynski A,Csizmadia E,et al.Effect of an experimental proteasome inhibitor on the cytoskeleton,cytosolic protein turnover,and induction in the neuronal cells in vitro.Neurotoxicology,2008,29:232-243.
  • 8Shin YK,Jang SY,Lee HK,et al.Pathological adaptive responses of Schwann cells to endoplasmic reticulum stress in bortezomibinduced peripheral neuropathy.Glia,2010,58:1961-1976.
  • 9王洪涛,刘卓刚,杨威,廖爱军,张嵘,吴斌,王慧涵,姚鲲,李迎春.硼替佐米致周围神经病变的机制及还原型谷胱甘肽逆转神经毒性的研究[J].中华血液学杂志,2011,32(2):107-111. 被引量:10
  • 10Durrant D,Liu J,Yang HS,et al.The bortezomib-induced mitochondrial damage is mediated by accumulation of active protein kinase C-delta.Biochem Biophys Res Commun,2004,321:905-908.

二级参考文献10

  • 1Andreas AA,Gregoris I,Haralabos PK.Bortezomib-induced peripheral neuropathy in multiple myeloma:a comprehensive review of the literature.Blood,2008,112:1593-1599.
  • 2Ocean AJ,Vahdat LT.Chemotherapy-induced peripheral neuropathy:pathogenesis and emerging therapies.Support Care Cancer,2004,12:619-625.
  • 3Cavaletti G,Gilardini A,Canta A,et al.Bortezomib induced peripheral neurotoxicity:a neurophysiological and pathological study in the rat.Exp Neurol,2007,204:317-325.
  • 4Cavaletti G,Tredici G,Marmiroli P,et al.Morphometric study of the sensory neuron and peripheral nerve changes induced by chronic cisplatin (DDP) administration in rats.Acta Neuropathol,1992,84:364-371.
  • 5McDonald ES,Randon KR,Knight A,et al.Cisplatin preferentially binds to DNA in dorsal root ganglion neurons in vitro and in vivo:a potential mechanism for neurotoxicity.Neurobio Dis,2005,18:305-313.
  • 6Kikuchi S,Shinpo K,Tsuji S,et al.Effect of proteasome inhibitor on cultured mesencephalic dopaminergic neurons.Brain Res,2003,964:228-236.
  • 7Richardson PG,Sonneveld P,Schuster MW,et al.Bortezomib or high-dose dexamethasone for relapsed multiple myeloma.Engl J Med,2005,352:2487-2498.
  • 8Pei XY,Dai Y,Grant S.Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors.Clin Cancer Res,2004,10:3839-3852.
  • 9Qin JZ,Ziffra J,Stennett L,et al.Proteasome inhibitors trigger NOXA-mediated apoptosis in melanoma and myeloma cells.Cancer Res,2005,65:6282-6293.
  • 10Landowski TH,Megli CJ,Nullmeyer KD,et al.Mitochondrialmediated disregulation of Ca^2+ is a critical determinant of Velcade (PS-341/bortezomib) cytotoxicity in myeloma cell lines.Cancer Res,2005,65:3828-3836.

共引文献9

同被引文献23

  • 1亢卉.硼替佐米在恶性血液病中的作用机制[J].中国新药与临床杂志,2006,25(6):459-462. 被引量:9
  • 2MEISTER S,SCHUBERT U,NEUBERT K,et al.Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition[J].Cancer Res,2007,67(4):1783-1792.
  • 3ROSINOL L,MONTOTO S,CIBEIRA MT,et al.Bortezomibinduced severe hepatitis in multiple myeloma:a case report[J].Arch Intern Med,2005,165(4):464-465.
  • 4PLASMATI R,PASTORELLI F,CAVO M,et al.Neuropathy in multiple myeloma treated with thalidomide:a prospective study[J].Neurology,2007,69(6):573-581.
  • 5RICHARDSON PG,XIE W,MITSIADES C,et al.Single-agent bortezomib in previously untreated multiple myeloma:efficacy,characterization of peripheral neuropathy,and molecular correlations with response and neuropathy[J].J Clin Oncol,2009,27(21):3518-3525.
  • 6MORAWSKA M,GRZASKO N,KOSTYRA M,et al.Therapyrelated peripheral neuropathy in multiple myeloma patients[J].Hematol Oncol,2015,33(4):113-119.
  • 7RICHARDSON PG,BARLOGIE B,BERENSON J,et al.A phase 2 study of bortezomib in relapsed,refractory myeloma[J].N Engl J Med,2003,348(26):2609-2617.
  • 8JAGANNATH S,BARLOGIE B,BERENSON J,et al.A phase2 study of two doses of bortezomib in relapsed or refractory myeloma[J].Br J Haematol,2004,127(2):165-172.
  • 9RICHARDSON PG,SONNEVELD P,SCHUSTER M,et al.Extended follow-up of a phase 3 trial in relapsed of the APEX trial[J].Blood,2007,110(10):3557-3560.
  • 10MOREAU P,PYLYPENKO H,GROSICKI S,et al.Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma:a randomized,phase 3,non inferiority study[J].Lancet Oncol,2011,12(5):431-440.

引证文献3

二级引证文献16

;
使用帮助 返回顶部